Showing results (871-880 of 917) with videos related to

Sort By:
Pageof 92
Mutation Research|June 9, 2012
Ionizing radiation biomarkers for potential use in epidemiological studiesEileen Pernot, Janet Hall, Sarah Baatout, et al.
Molecular Cancer|September 13, 2024
Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomicsSophie Cousin, Jean-Philippe Guégan, Kohei Shitara, et al.
Annals of Surgical Oncology|June 10, 2020
A Standard Set of Value-Based Patient-Centered Outcomes for Pancreatic Carcinoma: An International Delphi SurveyZineb Cherkaoui, Cristians González, Taiga Wakabayashi, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|July 4, 2019
Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significanceSimon Pernot, Magali Terme, Nina Radosevic-Robin, et al.
JACC. Cardiovascular Interventions|February 18, 2019
Transcarotid Approach for Transcatheter Aortic Valve Replacement With the Sapien 3 Prosthesis: A Multicenter French RegistryPavel Overtchouk, Thierry Folliguet, Frédéric Pinaud, et al.
European Journal of Cancer (Oxford, England : 1990)|July 21, 2025
Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitorsClaire Gallois, Margherita Ambrosini, Sara Lonardi, et al.
Experimental Hematology & Oncology|July 21, 2023
DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching studyStefano Kim, Véronique Vendrely, Angélique Saint, et al.
Cancer Treatment Reviews|July 1, 2026
Antiangiogenic therapies in gastric cancer: future directions for 2026 and beyond: an UNICANCER gastrointestinal group (UCGI) perspectiveJudith Raimbourg, Meher Ben Abdelghani, Valerie Boige, et al.
The Lancet. Oncology|April 26, 2025
TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trialAziz Zaanan, Olivier Bouché, Christelle de la Fouchardière, et al.
EMBO Molecular Medicine|February 17, 2025
Repression of apelin Furin cleavage sites provides antimetastatic strategy in colorectal cancerBéatrice Demoures, Fabienne Soulet, Jean Descarpentrie, et al.
Pageof 92